EUVIMEDEUVIMED entdecken
Korrektur

Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab

JNCI: Journal of the National Cancer Institute · 12.11.2026

DOI: 10.1093/jnci/djag367 ↗

Kurz gefasst

Korrektur in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 12.11.2026. Die Arbeit nennt 3 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djag367

Vancouver

Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab. JNCI: Journal of the National Cancer Institute. 2026. doi:10.1093/jnci/djag367

BibTeX
@article{euvimed2026,
  title = {Correction to: Impact of KRAS codon-specific mutations on survival in metastatic CRC on trifluridine-tipiracil with/without bevacizumab},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2026},
  doi = {10.1093/jnci/djag367}
}
Kostenlos starten →